secondary progressive multiple sclerosis
Biogen expands portfolio in deal with Alcyone Therapeutics
The agreement gives Biogen full rights to a potential therapy for patients with neurological disorders
Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study
Approximately 2.9 million people worldwide are living with the neurodegenerative disease
Sanofi’s investigational frexalimab shows promise in relapsing MS study
Approximately 2.9 million people worldwide are affected by the neurological disease
Roche and Ascidian enter neurological disease partnership worth over $1.8bn
More than three billion people worldwide were living with a neurological condition in 2021
Tiziana shares promising results for intranasal foralumab in secondary progressive MS
The neurological disease is estimated to affect 2.8 million people globally
Tiziana shares promising results for intranasal foralumab in multiple sclerosis
The neurological disease affects approximately 2.8 million people worldwide
Study reveals molecular signatures driving immune cell attacks in chronic neurological diseases
MS is a chronic neurological disease that affects more than two million people worldwide
New genetic risk tool could predict multiple sclerosis in young adults much earlier
Approximately 2.8 million people worldwide are affected by the disabling neurological disease
Sanofi’s investigational frexalimab shows promise in relapsing forms of MS
Results from a mid-stage of the candidate were recently published in the NEJM
UK government announces nearly £50m to expand dementia research sites
The funding will be used to enable more people to take part in clinical trials for dementia
Michael J Fox Foundation awards Vesper Bio over $870,000 for Parkinson’s treatment
Vesper is currently developing VES001 for GRN-mutated frontotemporal dementia
New framework establishes two tests for use in clinical trials for Parkinson’s
The neurological condition currently affects around 145,000 people in the UK